Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fusidic acid oral - Arrevus

Drug Profile

Fusidic acid oral - Arrevus

Alternative Names: ARV-1801; CEM-102; SQ-16603; Taksta

Latest Information Update: 07 Feb 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cempra Pharmaceuticals
  • Developer Arrevus
  • Class Antibacterials; Cholestadienes; Sterols
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Bone and joint infections
  • New Molecular Entity No

Highest Development Phases

  • Phase III Skin and soft tissue infections
  • Phase II/III Bone and joint infections
  • Discontinued Cystic fibrosis-associated respiratory tract infections; Osteomyelitis

Most Recent Events

  • 07 Feb 2019 Discontinued - Phase-I for Cystic fibrosis-associated respiratory tract infections in USA (PO)
  • 07 Feb 2019 Discontinued - Phase-I for Osteomyelitis in USA (PO)
  • 05 Feb 2019 Arrevus acquires oral fusidic acid from Melinta Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top